Pulike Biological Engineering Inc Class A 603566
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥12.97
- Day Range
- ¥13.31–14.27
- 52-Week Range
- ¥10.80–25.00
- Bid/Ask
- ¥14.12 / ¥14.13
- Market Cap
- ¥4.89 Bil
- Volume/Avg
- 10.1 Mil / 2.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- 49.37
- Price/Sales
- 4.46
- Dividend Yield (Trailing)
- 4.96%
- Dividend Yield (Forward)
- 4.96%
- Total Yield
- 4.96%
Company Profile
Pulike Biological Engineering Inc is engaged in the research and development and production and operation of veterinary drugs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,679
- Website
- http://www.pulike.com.cn
Comparables
Valuation
|
Metric
|
603566
|
688739
|
301207
|
|---|---|---|---|
Price/Earnings (Normalized) | 49.37 | 32.41 | 17.92 |
Price/Book Value | 1.86 | 1.25 | 2.11 |
Price/Sales | 4.46 | 6.72 | 5.45 |
Price/Cash Flow | 19.95 | 19.01 | 13.22 |
Price/Earnings
603566
688739
301207
Financial Strength
|
Metric
|
603566
|
688739
|
301207
|
|---|---|---|---|
Quick Ratio | 2.23 | 17.26 | 2.85 |
Current Ratio | 2.70 | 18.49 | 3.42 |
Interest Coverage | 944.40 | 288.58 | 149.96 |
Quick Ratio
603566
688739
301207
Profitability
|
Metric
|
603566
|
688739
|
301207
|
|---|---|---|---|
Return on Assets (Normalized) | 3.00% | 3.14% | 9.24% |
Return on Equity (Normalized) | 3.58% | 3.29% | 11.52% |
Return on Invested Capital (Normalized) | 3.44% | 2.81% | 10.82% |
Return on Assets
603566
688739
301207
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kydfvyjx | Vdyyn | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zbxqxrkw | Tjgvgd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wmbtmyfd | Tlpvmqx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ytnhxkm | Mfpndx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rkldcfjf | Hzlhw | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qsvbnnycb | Vplvf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wwczwnjzz | Snkb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Tqtnqwf | Mmfk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tmykvqb | Zmnhcx | $13.4 Bil | |||
| Incyte Corp
INCY
| Wyjplhbc | Gnhvgp | $12.7 Bil |
United States